GLP-1 drugs like semaglutide reduce heart attack, stroke, and cardiovascular death risk in people with obesity. New research reveals vascular insulin responsiveness may be the key mechanism behind these benefits.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Semaglutide improves vascular responsiveness to insulin
GLP-1 Receptor Agonists Drug class
Weight Loss, Reduced Heart Attack And Stroke Risk Primary benefits
Mouse Model Study model
Vascular Insulin Responsiveness Key mechanism
Substantially Reduced cardiovascular death risk
Highly Effective weight loss effectiveness